• br Implementation of sacubitril valsartan into clinical prac

  2024-08-06

  

  Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio

• br STAR Methods br AMPK A Therapeutic Target

  2024-08-06

  

  STAR★Methods AMPK: A Therapeutic Target in the β Cell? Loss of pancreatic β cell function is a hallmark of the transition to a diagnosis of T2DM (see Glossary) 1, 2, 3, 4. AMPK activation has gained attention for the treatment of hyperglycemia in prediabetes as an insulin-sensitizing agent bec

• Introduction Induction of long term

  2024-08-06

  

  Introduction Induction of long-term potentiation (LTP), the cellular correlate of learning and memory, triggers profound changes in the structure and function of excitatory synapses by increasing dendritic spine size and synaptic strength. Significant progress has been made in understanding the int

• Introduction Increasing environmental pollution caused by

  2024-08-06

  

  Introduction Increasing environmental pollution caused by heavy metals, originating mainly from industrial processes and urban activities, as well as the widespread application of pesticides, fertilizers, manure and sewage sludge, has posed a serious problem for safe food production and become a po

• We next developed a system for staging severity Our guiding

  2024-08-06

  

  We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u

• br Materials and methods br

  2024-08-06

  

  Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi

• br Conclusions Several lines of

  2024-08-06

  

  Conclusions Several lines of evidence have been established, which support the adenosine kinase hypothesis of epileptogenesis, which is based on a sequence of events leading from acute D4476 injury to initial downregulation of ADK, rise in extracellular adenosine, changes in astrocytic adenosine

• Levonorgestrel receptor br Introduction Myasthenia gravis MG

  2024-08-06

  

  Introduction Myasthenia gravis (MG) is an autoimmune disease in which antibodies against targets on the postsynaptic muscle membrane cause neuromuscular transmission failure. About 85% of patients with MG have autoantibodies against Levonorgestrel receptor receptor (AChR) [1]. In AChR negative MG

• In conclusion AXL overexpression preexisted

  2024-08-05

  

  In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi

• Compound was docked into the active site of Aurora

  2024-08-05

  

  Compound was docked into the active site of Aurora B kinase using Tripos sybyl-X ver. 2.1.1. The crystal structure of human Aurora B kinase cocrystallized with its potent inhibitor VX-680 was used for the docking analysis (PDB ID: ). The most likely binding conformations were selected based on the d

• PF also a dual Aurora A and Aurora

  2024-08-05

  

  PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly jak inhibitor for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the MTD was de

• V ATPase is a complex enzyme that is composed

  2024-08-05

  

  V-ATPase is a complex enzyme that is composed of several subunits, which are assembled into two domains: trans-membrane (V0) and cytosolic (V1) domains [3,5]. Epididymal epithelial Dexmedetomidine HCl mg of rats has been reported to contain V-ATPase which is distributed at the apical pole of the nar

• Treatment of all of the GYN

  2024-08-05

  

  Treatment of all of the GYN cancer Carbamazepine in this study with ATRi not only reduced phosphorylation of Chk1 at Ser345 following genotoxic stress, but also phosphorylation of ATM. Loss of phospho-ATM following ATRi treatment is not likely due to non-specific targeting of ATM by ETP-46464 [28].

• br Experimental Procedures br Acknowledgments This work

  2024-08-05

  

  Experimental Procedures Acknowledgments This work was supported by NIH/National Human Genome Research Institute (NHGRI)R00 HG006922 and NIH/NHGRIR01 HG008974 (to J.G.), the Huntsman Cancer Institute, and the Women’s Cancers Disease-Oriented Team at the Huntsman Cancer Institute. Research repor

• br Materials and methods br Results RT

  2024-08-05

  

  Materials and methods Results RT-PCR showed that both arginase 1 and 2 were expressed in the OB of Korean roe deer (Fig. 1). Immunoblotting detected arginase 1 in the OB of roe deer (Fig. 2A, left lane) at a molecular weight of approximately 37kDa, which is the size of the enzyme in the rat O

17061 records 134/1138 page Previous Next First page 上5页 131132133134135 下5页 Last page